ASP Isotopes Inc. Reports $4.89 Million Revenue and $12.87 Million Net Loss for Quarter Ending September 30, 2025

ASP Isotopes Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenue of $4.89 million for the quarter, a substantial increase from $1.09 million in the same period last year. This growth was driven by the introduction of construction services revenue following the acquisition of Skyline Builders Group Holding Ltd. in August 2025, which contributed $3.62 million. Product revenue from nuclear medical doses for PET scanning also rose to $1.27 million, up from $1.09 million year-over-year. However, the company incurred a net loss of $12.87 million, compared to a loss of $7.27 million in the prior year, reflecting increased operating expenses primarily due to higher research and development costs and selling, general, and administrative expenses.

The company’s total assets surged to $225.89 million as of September 30, 2025, compared to $94.35 million at the end of 2024. This increase was largely attributed to cash and cash equivalents, which rose to $113.94 million from $61.89 million, following successful capital raises totaling approximately $110 million from common stock issuances earlier in the year. The company’s liabilities also increased significantly, with total liabilities reaching $129.29 million, up from $43.18 million, primarily due to the issuance of convertible notes payable, which amounted to $97.98 million.

Operationally, ASP Isotopes has made strides in expanding its isotope production capabilities. The company commenced commercial production of enriched isotopes at its facilities in Pretoria, South Africa, and anticipates shipping its first commercial batches of enriched Carbon-12, Silicon-28, and Ytterbium-176 in the coming quarters. The company is also planning additional isotope enrichment plants in South Africa, Iceland, and the United States. As of September 30, 2025, ASP Isotopes had a total employee headcount of 200, reflecting its growth and expansion efforts.

Looking ahead, ASP Isotopes has outlined a strategic plan to separate its Nuclear Fuels business from its Specialist Isotopes and Related Services business, aiming for a public listing of Quantum Leap Energy (QLE) by the end of 2025. The company has also entered into a loan agreement with TerraPower for the construction of a uranium enrichment facility, which is expected to further enhance its operational capabilities. However, the company cautioned that it will need to continue raising capital to support its operations and growth initiatives, as it has not yet achieved positive cash flows from operations. The outlook remains contingent on successful execution of its strategic initiatives and market conditions.